Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 79922

Title: Challenges for clinicians treating autoimmune pancreatitis: Current perspectives

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05572940
Position: Editorial Board
Academic degree: MD, PhD
Professional title: Assistant Professor
Reviewer's Country/Territory: Japan
Author's Country/Territory: South Korea

Manuscript submission date: 2022-09-12

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-09-26 01:36

Reviewer performed review: 2022-09-26 02:12

Review time: 1 Hour

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [Y] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No
Peer-reviewer	Peer-Review: [Y] Anonymous [ ] Onymous

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

statements	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

This is a review article showing the current perspectives of autoimmune pancreatitis. This may be interest to the readers of this journal. However, there are some problems. #1 Recently, cases of pancreatic cancer or cholangiocarcinoma complicating autoimmune pancreatitis have been reported. We recommend additional references and discussion of the association with these malignancies. #2 The most important question for the patient is whether AIP is a life-threatening disease. More discussion of life prognosis is needed. #3 It is well known that in AIP, steroid treatment improves pancreatic swelling and decreases serum IgG4 levels. So, does it also improve the exocrine and endocrine functions of the pancreas? #4 In AIP with biliary obstruction, bile duct stenting via ERCP is performed. However, is stenting necessary in all obstruction cases? Is it acceptable to start steroid therapy first? Please indicate the treatment strategy for AIP complicated with obstructive jaundice.

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 79922

Title: Challenges for clinicians treating autoimmune pancreatitis: Current perspectives

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 00724362
Position: Editorial Board
Academic degree: MD, PhD
Professional title: Associate Professor, Doctor
Reviewer's Country/Territory: Sweden
Author's Country/Territory: South Korea

Manuscript submission date: 2022-09-12

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-09-28 10:52

Reviewer performed review: 2022-09-28 11:51

Review time: 1 Hour

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [Y] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No
Peer-reviewer	Peer-Review: [Y] Anonymous [ ] Onymous

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

statements	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

I suggest inclusion of the following topics to improve the quality of the manuscript: In this kind of article, it is the most important to emphasize following: - IgG4 serum level alone lacks sensitivity and specificity but can be helpful to establish the diagnosis of AIP type 1, and therefore should be measured if IgG4-related gastrointestinal disease is suspected (normal serum IgG4 does not exclude AIP type 1). - IgG4 serum levels seem to have diagnostic value when the level is higher than four times the upper level of normal, which is the case in only a minority of patients - As with its poor quality in establishing the diagnosis of IgG4-related disease serum, IgG4 levels cannot contribute to accurately monitoring disease course, nor does it sufficiently correlate with the development of complications or even with relapse - Although an increased IgG4 plasma cell count is an important finding, it is not diagnostic of AIP type 1 if found in isolation - A biopsy showing little, or no evidence of AIP cannot be used in isolation to exclude this diagnosis, unless a positive alternative diagnosis can be made - For the diagnosis of AIP, the number of IgG4+ plasma cells should exceed 50 cells/high-power field (HPF) in surgical specimens and 10 cells/HPF in biopsy samples (average of counts in three hot spots. In addition, the IgG4/IgG ratio should be more than 40%. You can discuss differences between ICDC and pathological classification criteria. Authors did not mention risk of pancreatic cancer in AIP and in IgG4 in general. How these patients (AIP) are followed? Other comments: Pancreatic exocrine insufficiency and diabetes mellitus occur commonly in AIP. AIP type 2 is just barely mentioned. AIP NOS is not mentioned – it is a part of ICDC classification 1-2 in the sub-title you use abbreviation ERCP and in the text ERP What is the role of surgery in AIP? I suggest reading and citing following articles: United European Gastroenterology evidence-based guidelines

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

for the diagnosis and therapy of chronic pancreatitis (HaPanEU) - PubMed (nih.gov) European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations - PubMed (nih.gov) Unraveling the relationship between autoimmune pancreatitis type 2 and inflammatory bowel disease: Results from two centers and systematic review of the literature - PubMed (nih.gov) Incidence of endocrine and exocrine insufficiency in patients with autoimmune pancreatitis at diagnosis and after treatment: a systematic review and meta-analysis - PubMed (nih.gov) The Clinical Utility of Soluble Serum Biomarkers in Autoimmune Pancreatitis: A Systematic Review - PubMed (nih.gov) Pancreatic cancer in patients with autoimmune pancreatitis: A scoping review - PubMed (nih.gov) Efficacy and safety of rituximab for IgG4-related pancreato-biliary disease: A systematic review and meta-analysis - PubMed (nih.gov)

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 79922

Title: Challenges for clinicians treating autoimmune pancreatitis: Current perspectives

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03258917
Position: Editorial Board
Academic degree: PhD
Professional title: Professor, Senior Scientist
Reviewer's Country/Territory: Spain
Author's Country/Territory: South Korea

Manuscript submission date: 2022-09-12

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-09-12 17:28

Reviewer performed review: 2022-09-29 14:50

Review time: 16 Days and 21 Hours

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [Y] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [Y] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No
Peer-reviewer	Peer-Review: [Y] Anonymous [ ] Onymous

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

statements	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Authors should include a brief paragraph/point indicating the main limitations observed in the field. Also it will be desiderable to include their expert clinical opinion. What are the advantages and novelty of their manuscript compared to those of Khandelwal A et al., 2020 (PMID: 31650376), Goyal S et al., 2021 (PMID: 34135159) or Okazaki K, et al., 2017 (PMID: 28027896).

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 79922

Title: Challenges for clinicians treating autoimmune pancreatitis: Current perspectives

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06232664
Position: Peer Reviewer
Academic degree: MD
Professional title: Doctor
Reviewer's Country/Territory: Sweden
Author's Country/Territory: South Korea

Manuscript submission date: 2022-09-12

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-09-12 21:28

Reviewer performed review: 2022-10-04 12:22

Review time: 21 Days and 14 Hours

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [Y] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No
Peer-reviewer	Peer-Review: [Y] Anonymous [ ] Onymous

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

statements	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

This comprehensive review addresses a topic of great interest for clinical practice. It is written in a coherent style that is impressive considering the complexity of the topic. Apart from a comprehensive overview of the diagnosis and management of AIP, the differential diagnosis between PDAC and AIP has been addressed, which represents one of the burning issues in Pancreatology. Taken together, the authors are to be commended on keeping abreast of the major recent developments in the field. The manuscript is supported by informative figures and tables, the choice of references is up to date and the language style is easy to follow. Only a few minor issues: Please address biomarkers other than IgG4 in short. This reviewer would not agree that ANA are helpful in identifying AIP in some cases (rows 206-207), as ANA is rather a non-specific marker of autoimmunity, thus considered obsolete for AIP diagnosis. For a detailed overview of biomarkers in AIP authors could have a look at [1]. This comprehensive review addresses a topic of great interest for clinical practice. It is written in a coherent style that is impressive considering the complexity of the topic. Apart from a comprehensive overview of the diagnosis and management of AIP, the differential diagnosis between PDAC and AIP has been addressed, which represents one of the burning issues in Pancreatology. Taken together, the authors are to be commended on keeping abreast of the major recent developments in the field. The manuscript is supported by informative figures and tables, the choice of references is up to date and the language style is easy to follow. Only a few minor issues: Please address biomarkers other than IgG4 in short. This reviewer would not agree that ANA are helpful in identifying AIP in some cases (rows 206-207), as ANA is rather a non-specific marker of autoimmunity, thus considered obsolete for AIP diagnosis. For a detailed

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

overview of biomarkers in AIP authors could have a look at [1]. 1. Dugic A, Verdejo Gil C, Mellenthin C, Vujasinovic M, Löhr J-M, Mühldorfer S. The Clinical Utility of Soluble Serum Biomarkers in Autoimmune Pancreatitis: A Systematic Review. Biomedicines. 2022;10(7):1511.

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 79922

Title: Challenges for clinicians treating autoimmune pancreatitis: Current perspectives

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 00724362
Position: Editorial Board
Academic degree: MD, PhD

Professional title: Associate Professor, Doctor

Reviewer's Country/Territory: Sweden

Author's Country/Territory: South Korea

Manuscript submission date: 2022-09-12

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2022-11-02 14:16

Reviewer performed review: 2022-11-02 14:23

Review time: 1 Hour

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous Conflicts-of-Interest: [ ] Yes [Y] No

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

The authors answered on all reviwers' comments appropriately.